|
Product Report
|
|
Delivery Across the Blood-Brain Barrier
The blood-brain barrier (BBB) and the blood cerebrospinal fluid barrier
(BCSFB) exist to protect the brain, stringently regulating the passage
of substances in and out. This report examines the ways in which these
natural barriers may be overcome or circumvented to ensure that drugs
can reach their intended target in the brain.
|
|
Read more...
|
|
|
Market Report
|
|
New Emerging R&D and Clinical Trial Locations
This report examines and compares the next wave of clinical trial and
drug development locations. Over the next 5 to 10 years, the countries
identified in this report will become increasingly important as
offshoring and outsourcing destinations.
|
|
Read more...
|
|
|
Market Report
|
The CMO Market Outlook to 2017
This report examines the markets for contract manufacturing of finished
dose forms and clinical quantity pharmaceuticals. The report forecasts
CMO markets for the US, Western Europe, Eastern Europe, China, India,
Other Asia, Latin America and the rest of the world to 2017. Drivers and
restraints for each regional market as well as the global market are
also examined.
|
|
Read more...
|
|
|
Market Report
|
|
Avastin fails to top any individual market in 2011
The high level of commercial success experienced by the key companies in
the cancer therapy market makes the market extremely attractive to drug
developers. Treatment of cancer has shifted toward a more focused
attack on the disease with targeted therapies. However, austerity
packages imposed could see slower commercial growth and larger generic
erosion of key brands.
|
|
Read more...
|
|
|
Market Report
|
Drug Discovery for Rare Diseases
In comparison with major diseases, the targeting of rare diseases poses
many different challenges, necessitating consideration of bespoke
R&D strategies for drug discovery efforts to be successful. This
report examines the role that low disease prevalence plays in
determining the most suitable R&D path.
|
|
Read more...
|
|
|
Market Report
|
Drug Delivery Partnership Strategies
This report builds on interviews with industry executives, case studies,
and analysis of deal and other market data to set out a set of
strategies to optimally partner for enhanced drug delivery products.
|
|
Read more...
|
|
|
Product Report
|
|
Innovations in the Delivery of Peptides
Peptides are an important class of drugs, but their potential for
treating chronic diseases will be fully realized only if more acceptable
delivery methods than daily injections can be developed. Recognition of
this has led to advances in oral, intranasal, inhaled, transdermal, and
buccal formulations. This report analyses the products and companies at
the forefront of such research.
|
|
Read more...
|
|
|
Market Report
|
|
The Computed Tomography (CT) Market Outlook to 2016
This report provides comprehensive coverage of the global CT market,
covering low- to high-slice scanners and analyzing the major factors
affecting revenue growth. Quantitative estimates of revenue by market
segment and geography are provided. The report assesses the demand side
of the CT scanner business strategically analyzes the vendor competitive
landscape.
|
|
Read more...
|
|
|
Market Report
|
|
Innovations in Molecular Diagnostics for Infectious Diseases
This report examines the opportunities presented to the developers of
molecular diagnostics by the emergence of novel/variant pathogens and
ways in which new molecular testing technologies are being translated
into superior diagnostic products in areas such as healthcare-associated
infections; HPV infections, blood-borne viral infections and
respiratory viral infections.
|
|
Read more...
|
|
|
Market Report
|
Impact of Biomarkers in Alzheimer's Disease - Dx-Rx collaboration paves the way for personalized medicine
Diagnostic and prognostic biomarkers will help to identify patients with
early Alzheimer’s disease, while pharmacogenetic biomarkers can inform
prescribing decisions and form the basis of personalized medicine.
Biomarkers are at the heart of the development of two high-risk pipeline
drugs, bapineuzumab and solanezumab, with combined peak-year sales
forecasts of $6.6bn in the seven major markets.
|
|
Read more...
|
|
|
Market Report
|
|
Global Generics
Datamonitor's industry profiles are an essential resource for top-level
data and analysis. This profile includes data on market size and
segmentation, plus textual analysis of the key trends and competitive
landscape, demographic information, and descriptions of the leading
companies.
|
|
Read more...
|
|
|
Market Report
|
Generics in Japan
Datamonitor's industry profiles are an essential resource for top-level
data and analysis. This profile includes data on market size and
segmentation, plus textual analysis of the key trends and competitive
landscape, demographic information, and descriptions of the leading
companies.
|
|
Read more...
|
|
|
Market Report
|
|
Global Health Care Equipment
Datamonitor's industry profiles are an essential resource for top-level
data and analysis. This profile includes data on market size and
segmentation, plus textual analysis of the key trends and competitive
landscape, demographic information, and descriptions of the leading
companies.
|
|
Read more...
|
|
|
Market Report
|
|
OTC Pharmaceuticals: Global Industry Guide
OTC Pharmaceuticals: Global Industry Guide is an essential resource for
top-level data & analysis covering the OTC Pharmaceuticals industry.
It includes data on market size & segmentation, textual analysis of
the key trends & competitive landscape, & profiles of the
leading companies. This incisive report provides expert analysis on a
global, regional & country basis.
|
|
Read more...
|
|
|
Market Report
|
|
Trends in mHealth and Telemedicine
Worldwide societal, technological, and economic changes are affecting
the way people live and look after their health.
New, more efficient and cost effective ways of delivering healthcare are
needed.
mHealth and telemedicine offer a solution to this problem. The growth
potential of the mHealth and telemedicine market is only now becoming
apparent as more healthcare and ICT vendors take part.
|
|
Read more...
|
|
|
Market Report
|
|
Neurologists remain loyal to brands in genericized market
The epilepsy market has become increasingly competitive following the
launch of Vimpat (lacosamide; UCB) in the US in May 2009 and patent
expiries of the top four second-generation anticonvulsant drugs over
2008–09. However, the switching of stable epilepsy patients to a generic
alternative remains controversial due to physicians’ concerns
surrounding compromised seizure control.
|
|
Read more...
|
|
|
Market Report
|
|
Aging populations will lead to a growing number of active epilepsy diagnoses
Datamonitor has estimated that there were approximately 4.5 million
cases of diagnosed active epilepsy in 2010 in the seven major markets
(the US, Japan, France, Germany, Italy, Spain, and the UK). Almost half
of this patient population lives in the US. Datamonitor expects
prevalence rates to remain constant over the forecast period (2010–20).
|
|
Read more...
|
|
|
Market Report
|
|
Past successes hard to emulate in highly genericized market
Sales of antiepileptic drugs totaled $3.5 billion in 2009 across the
seven major markets (US, Japan, France, Germany, Italy, Spain and the
UK). Datamonitor anticipates the combination of continuing strong
historical growth dynamics and the uptake of the late-stage pipeline
drugs to result in the market value peaking at $5.1 billion in 2017,
after which a new wave of patent expiries hits the US.
|
|
Read more...
|
|